The saga of the latest breakthroughs in impotence treatments shows how the medical establishment may redefine a condition in a way that greatly increases the number of people "afflicted." It shows that Wall Street may adopt hyped statistics to increase markets; how pharmaceuticals companies may recruit influential doctors as consultants until few independent experts remain; how physician's safety concerns about new therapies may remain whispers that the public (and investors) are unlikely to hear. The story deals with the new pharmaceutical treatments for erectile dysfunction.
This file is not available for digital download. IRE members may place an order by emailing firstname.lastname@example.org